Brain Penetration of WEB 2086 (Apafant) and Dantrolene in Mdr1a (P-Glycoprotein) and Bcrp Knockout Rats
暂无分享,去创建一个
Holger Fuchs | Naoki Ishiguro | N. Ishiguro | Wataru Kishimoto | P. Tanswell | Dietmar Gansser | Paul Tanswell | D. Gansser | W. Kishimoto | H. Fuchs
[1] T. Ebner,et al. Impact of Endogenous Esterase Activity on In Vitro P-Glycoprotein Profiling of Dabigatran Etexilate in Caco-2 Monolayers , 2014, Drug Metabolism and Disposition.
[2] H. Wesseling,et al. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. , 1979, European journal of pharmacology.
[3] Qingcheng Mao,et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). , 2010, Current drug metabolism.
[4] T. Terasaki,et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. , 2013, Journal of pharmaceutical sciences.
[5] J. Nicolazzo,et al. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). , 2009, Current topics in medicinal chemistry.
[6] Mitchell E Taub,et al. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. , 2012, Journal of pharmaceutical sciences.
[7] A. Volz,et al. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] Sagar Agarwal,et al. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. , 2011, Current pharmaceutical design.
[9] S. Muldoon,et al. Intravenous Lecithin-Coated Microcrystals of Dantrolene Are Effective in the Treatment of Malignant Hyperthermia: An Investigation in Rats, Dogs, and Swine , 1996, Anesthesia and analgesia.
[10] K D Pettigrew,et al. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.
[11] Atsushi Ose,et al. Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds , 2008, Drug Metabolism and Disposition.
[12] J. W. Higgins,et al. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics , 2012, Drug Metabolism and Disposition.
[13] T. Terasaki,et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. , 2013, Molecular pharmaceutics.
[14] Takashi Suzuki,et al. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.
[15] E. Sands,et al. Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates , 2012, Drug Metabolism and Disposition.
[16] Xingrong Liu,et al. Use of Cassette Dosing Approach to Examine the Effects of P-Glycoprotein on the Brain and Cerebrospinal Fluid Concentrations in Wild-Type and P-Glycoprotein Knockout Rats , 2014, Drug Metabolism and Disposition.
[17] C. Bundgaard,et al. Species Comparison of In Vivo P-Glycoprotein-Mediated Brain Efflux Using mdr1a-Deficient Rats and Mice , 2012, Drug Metabolism and Disposition.
[18] H. Kusuhara,et al. Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.
[19] K. Goldstein,et al. Minor Compensatory Changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Do Not Detract from Their Utility in the Study of Transporter-Mediated Pharmacokinetics , 2013, Drug Metabolism and Disposition.